Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 69 references it cites were found in a registry or an index; none of the 57 sources its claims cite is checked for support yet.

Novel approaches in treatment of pediatric anxiety

Open access
Park, Jennifer M., Geller, Daniel A. · 2014 · F1000Prime Reports

Abstract

Pediatric anxiety disorders have high prevalence rates andmorbidity and are associated with considerable functional impairment and distress. They may be predictors for the development of other psychiatric disorders and, without intervention, are more likely to persist into adulthood. While evidence-based pharmacological and behavioral interventions are currently available, there remains a sizable subset of youth who remain only partially treatment-responsive and therefore symptomatic following treatment. Novel methods of treatment, pharmacologic and non-pharmacologic, including acceptance and commitment therapy (ACT), attention bias modification (ABM), d-cycloserine (DCS) augmentation of cognitive behavioral treatment (CBT), and glutamatergic agents such as riluzole, are briefly introduced and discussed. © 2014 Faculty of 1000 Ltd.

Overview

CoChat Summary

TL;DR

This review argues that although CBT and SSRIs are effective first-line treatments for pediatric anxiety, up to 50% of youth still meet criteria after treatment, motivating novel approaches. It briefly reviews emerging pharmacologic and non-pharmacologic strategies, especially ACT, attention bias modification, d-cycloserine, and riluzole.

Key findings

  • Pediatric anxiety disorders are common, with prevalence rates of 10% to 20%, and are linked to chronic impairment, comorbidity, and later anxiety or major depression if untreated.
  • In a multisite study cited by the paper, response rates were 81% for sertraline + CBT, 60% for CBT monotherapy, 55% for sertraline monotherapy, and 24% for placebo.
  • For attention bias modification (ABM), the paper reports:
  • 2 sessions increased attention disengagement from threat in chronically anxious children (mean age 10 years),
  • 4 sessions reduced clinician severity ratings in an RCT of children ages 8 to 14 years,
  • and ABM plus daily CBT produced greater symptom reductions than CBT alone in youth ages 13 to 17 years in a residential setting.
  • For riluzole in youth, a 12-week open-label study in 6 children/adolescents with treatment-resistant OCD found substantial symptom reduction in 4 of 6 participants, but a 12-week RCT in 60 youth found no significant difference versus placebo-augmented treatment.
  • For d-cycloserine (DCS) in youth, the paper states that one published study in children with OCD ages 8 to 17 years found no significant differences versus CBT alone, though effect sizes on primary outcomes were d = 0.31–0.47.

Methods

  • Narrative review of emerging treatments for pediatric anxiety disorders, with sections on non-pharmacologic and pharmacologic approaches.
  • Draws on previously published studies in children and adolescents, including case studies, open-label trials, RCTs, and adult trials cited for mechanistic or translational support.
  • Main analysis is descriptive synthesis of the literature rather than a new empirical dataset or meta-analysis.

Limitations

  • The paper itself notes that empirical research specifically examining ACT for pediatric anxiety disorders is sparse, and that there is a dearth of evidence for ACT in this population.
  • It also notes that the pediatric riluzole RCT may have been limited by sample characteristics and high rates of concomitant medications.
  • Evident from the text: this is a brief review, so conclusions are based on a small and heterogeneous set of studies rather than pooled quantitative analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.12703/p6-30

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 27 Not checked · 5 Own results and interpretations

14 more claims

Create a free account to see all 32 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 5
  • It may state two separate claims as one. 9

Create a free account to see these claims.

Citations

Cites

Show all 69 references

Cited by

See all 2

Metadata

Authors
Park, J. M., & Geller, D. A.
Affiliations
  • Massachusetts General Hospital (US)
  • Harvard University (US)
Corresponding author
Geller, Daniel A.
Venue
F1000Prime Reports
Published
2014-05-06
Volume
6
Pages
30-30
ISSN
2051-7599 (ISSN-L)
OpenAlex
W2001960276
Cited by
2
References
69
Citations by year
2025: 1 · 2019: 1
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • F1000Prime Reports (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
Keywords
childhood anxiety disorders, treatment-resistant anxiety, acceptance and commitment therapy, attentional bias modification, D-cycloserine, riluzole, glutamatergic agents, non-pharmacological treatment, pharmacotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel approaches in treatment of pediatric anxiety. https://app.cochat.ai/papers/10.12703/p6-30
The paper
Park, J. M., & Geller, D. A. (2014). Novel approaches in treatment of pediatric anxiety. F1000Prime Reports. https://doi.org/10.12703/p6-30

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.